FREE Account Opening + No Clearing Fees
Loading...

Ceigall India IPO vs Emcure Pharma IPO

Comparision between Ceigall India IPO and Emcure Pharma IPO.

IPO Details

Ceigall India IPO is a Mainline Book Built Issue IPO proposed to list at BSE, NSE while Emcure Pharma IPO is a Mainline Book Built Issue proposed to list at BSE, NSE.

Issue Size and Price

The total issue size of Ceigall India IPO is up to ₹1,252.66 Cr whereas the issue size of the Emcure Pharma IPO is up to ₹1,952.03 Cr. The final issue price of Ceigall India IPO is ₹401.00 per share and of Emcure Pharma IPO is ₹1,008.00 per share.

  Ceigall India IPO Emcure Pharma IPO
Face Value ₹5 per share ₹10 per share
Issue Price (Lower) ₹380.00 per share ₹960.00 per share
Issue Price (Upper) ₹401.00 per share ₹1,008.00 per share
Issue Price (Final) ₹401.00 per share ₹1,008.00 per share
Discount (Retail)
Discount (Employee) ₹38.00 per share ₹90.00 per share
Market Lot Size 37 shares 14 shares
Fresh Issue Size 1,70,63,640 shares 79,36,507 shares
Fresh Issue Size (Amount) up to ₹684.25 Cr up to ₹800.00 Cr
OFS Issue Size 1,41,74,840 shares 1,14,28,839 shares
OFS Issue Size (Amount) up to ₹568.41 Cr up to ₹1,152.03 Cr
Issue Size Total 3,12,38,480 shares 1,93,65,346 shares
Issue Size Total (Amount) up to ₹1,252.66 Cr up to ₹1,952.03 Cr

IPO Timetable

Ceigall India IPO opens on Aug 01, 2024, while Emcure Pharma IPO opens on Jul 03, 2024. The closing date of Ceigall India IPO and Emcure Pharma IPO is Aug 05, 2024, and Jul 05, 2024, respectively.

  Ceigall India IPO Emcure Pharma IPO
Anchor Bid Date Jul 31, 2024 Jul 02, 2024
Issue Open Aug 01, 2024 Jul 03, 2024
Issue Close Aug 05, 2024 Jul 05, 2024
Basis Of Allotment (Tentative) Aug 06, 2024 Jul 08, 2024
Initiation of Refunds (Tentative) Aug 07, 2024 Jul 09, 2024
Credit of Share (Tentative) Aug 07, 2024 Jul 09, 2024
Listing date (Tentative) Aug 08, 2024 Jul 10, 2024
Anchor Lockin End date 1 Sep 05, 2024 Aug 07, 2024
Anchor Lockin End date 2 Nov 04, 2024 Oct 06, 2024

Financials

Ceigall India IPO P/E ratio is 20.67, as compared to Emcure Pharma IPO P/E ratio of 34.55.

  Ceigall India IPO Emcure Pharma IPO
Financial

Ceigall India Limited Financial Information (Restated Consolidated)

Ceigall India Limited's revenue increased by 46.92% and profit after tax (PAT) rose by 81.81% between the financial year ending with March 31, 2024 and March 31, 2023.

Period Ended31 Mar 202431 Mar 202331 Mar 2022
Assets2,592.191,827.82959.14
Revenue3,066.192,087.041,146.50
Profit After Tax304.91167.70126.43
Net Worth906.41593.06431.25
Total Borrowing1,811.021,252.58652.12
Amount in ₹ Crore

Emcure Pharmaceuticals Limited Financial Information (Restated Consolidated)

Emcure Pharmaceuticals Limited's revenue increased by 11.33% and profit after tax (PAT) dropped by -6.1% between the financial year ending with March 31, 2024 and March 31, 2023.

Period Ended31 Mar 202431 Mar 202331 Mar 2022
Assets7,806.166,672.536,063.47
Revenue6,715.246,031.725,918.86
Profit After Tax527.58561.85702.56
Net Worth2,952.282,501.131,987.55
Reserves and Surplus2,722.402,293.771,791.03
Total Borrowing2,091.942,202.422,102.19
Amount in ₹ Crore
Promoter Shareholding (Pre-Issue) 99.99% 98.90%
Promoter Shareholding (Post-Issue) 82.06% 78.24%
P/E Ratio 20.67 34.55
Market Cap ₹6985.41 Cr. ₹19029.89 Cr.
ROE 33.57%% 16.90%%
ROCE 31.98%% 19.37%%
Debt/Equity 1.17 0.67
EPS ₹19.40 ₹29.17
RoNW 33.57%% 16.87%%

Shares Offered

In the Ceigall India IPO retail investors (RII) are offered 1,09,16,012 shares while in Emcure Pharma IPO retail investors are offered 1,09,16,012 shares. Qualified institutional buyers (QIB) are offered 62,37,721 shares in Ceigall India IPO and 38,53,234 shares in Emcure Pharma IPO.

  Ceigall India IPO Emcure Pharma IPO
Anchor Investor Reserveration 93,56,581 shares 57,79,850 shares
Market Maker Reserveration
QIB 62,37,721 shares 38,53,234 shares
NII 46,78,291 shares 28,89,926 shares
RII 1,09,16,012 shares 67,43,160 shares
Employee 55,096 shares 1,08,900 shares
Others
Total 2,18,87,120 shares 1,37,03,538 shares

Bids Received (Subscription)

Ceigall India IPO subscribed 14.01x in total, whereas Emcure Pharma IPO subscribed 67.87x.

  Ceigall India IPO Emcure Pharma IPO
QIB (times) 31.26x 191.24x
NII (times) 14.83x 49.32x
Big NII (times) 16.28x 54.90x
Small NII (times) 11.92x 38.16x
RII (times) 3.82x 7.36x
Employee (times) 11.84x 8.81x
Other (times)
Total (times) 14.01x 67.87x

Comments

Add a public comment...